Abstract
The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 374-386 |
| Number of pages | 13 |
| Journal | Leukemia and Lymphoma |
| Volume | 52 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2011 |
Keywords
- Immunotherapeutic approaches
- chemotherapeutic approaches
- lymphoid leukemia
- pharmacotherapeutics
- signaling therapies
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research